Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus - Wikidata - wikimedia - TriplyDB

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

http://www.wikidata.org/entity/Q24556635

about

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing Crystal Structures of the Glycopeptide Sulfotransferase Teg12 in a Complex with the Teicoplanin Aglycone The 2.7 Å resolution structure of the glycopeptide sulfotransferase Teg14 Regioselective deacetylation based on teicoplanin-complexed Orf2* crystal structures Interception of teicoplanin oxidation intermediates yields new antimicrobial scaffolds Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?Update on the emerging role of telavancin in hospital-acquired infections Management of multidrug-resistant enterococcal infections An antimicrobial peptidomimetic induces Mucorales cell death through mitochondria-mediated apoptosis Newer antibacterial drugs for a new century.Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.Newly Isolated Paenibacillus tyrfis sp. nov., from Malaysian Tropical Peat Swamp Soil with Broad Spectrum Antimicrobial Activity.N-thiolated beta-lactams: Studies on the mode of action and identification of a primary cellular target in Staphylococcus aureus.Cloning and characterization of new glycopeptide gene clusters found in an environmental DNA megalibrary Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection.5-Hydroxyethyl-3-tetradecanoyltetramic acid represents a novel treatment for intravascular catheter infections due to Staphylococcus aureus Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.Postgenomic strategies in antibacterial drug discovery.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.Total synthesis of [Ψ[C(═NH)NH]Tpg(4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study Vancomycin: ligand recognition, dimerization and super-complex formation.Telavancin: a new lipoglycopeptide with multiple mechanisms of action.Role of telavancin in treatment of skin and skin structure infections Syntheses and evaluation of macrocyclic engelhardione analogs as antitubercular and antibacterial agents.Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.Efficacy of the new lantibiotic NAI-107 in experimental infections induced by multidrug-resistant Gram-positive pathogens.Macrocyclic drugs and synthetic methodologies toward macrocycles Current and novel antibiotics against resistant Gram-positive bacteria Current strategies for the prevention and management of central line-associated bloodstream infections.Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections Structure diversification of vancomycin through peptide-catalyzed, site-selective lipidation: a catalysis-based approach to combat glycopeptide-resistant pathogens.Total syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptide Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment.

P2860

Q24606291-30B008C4-0C61-4D61-9F58-DC820C02D7D7 Q27660400-52CAA5AC-482D-4931-932C-D4F8E9BB1066 Q27666133-CBD2C5C7-D613-4A29-992C-1876B5532278 Q27666579-DB8E8C07-6812-4A7F-B1BE-A8BA280E3003 Q27667190-E401C90D-B3C3-441A-88D8-72D16D86B779 Q28078557-C904853A-12F5-4AC6-AF78-AE22FBDEFCB9 Q28083522-91D694F6-C0CF-42DE-B2E9-B3542B83BEE6 Q28285907-F5C6F352-A797-45A7-9DA8-5CA6B02BC5C2 Q28534020-7C0717C7-94A0-464A-AEAC-5F15F84933A6 Q30433333-2CDE21B3-721A-470B-BE07-AB4EE57914A3 Q30727582-FE2FCF83-E789-4AFB-BF7E-89D25245A195 Q31057909-2870EE83-641D-4C3E-9536-5A30A65A09FD Q31096170-600469C9-6881-4540-81F0-321E0913B782 Q33382969-67D99BAA-ACBA-4A9D-86B2-3040DD795EDF Q33559043-E81E03FB-E30B-4539-8D79-E91E375BB80C Q33589815-577A9C8C-A891-4250-97BA-DE2338A6055F Q33657212-D7A486CC-3DE6-4B41-9669-7ADFE8AF8BC6 Q33723124-F0DB39D6-26B6-4733-9ECA-E7EC4FCA80F8 Q33745572-CA0F8F4F-0891-4B1A-B6EF-2A9EA16B7B87 Q33788308-9C3E6CD2-902E-4EEA-9B05-48C037A73EC5 Q33876626-144FFB58-AC36-4399-B4B6-68C8B8F60632 Q34077052-4973CA35-B57C-4D28-B81F-C78999E59269 Q34282738-D30E667B-8D20-4305-9CBE-D2216E80EB4C Q34390763-D853419A-F4A2-41C9-A1B9-A7D5060018F2 Q34405922-656C3AB5-BB9E-4B44-A8D7-D8D12670882D Q34509652-5461E6F3-0FB0-483F-8457-AAFDE4223883 Q34539275-FBA763ED-3434-4D3E-990D-73821002EB70 Q34572923-7887BD4F-81E9-41E2-A90D-2ED81B61BD16 Q34620329-B0DC167E-7DCF-4C5B-B706-938F726E00C6 Q34645907-503A2ED8-182B-4DC4-B7CD-4E7DFF9DD40E Q34677611-5AB60B2C-194E-4CC8-85B5-F9A4116ED431 Q34699108-08143264-3EE5-43E1-9DDD-99CF8B088EE2 Q34737510-7EB5BC38-08EE-4B04-B768-BD2FB6E4C681 Q34740721-21F642CC-0566-4208-8B00-BE6750F1E975 Q35026521-2FF31937-F1A8-4621-AB55-1DFE4389B697 Q35026591-FA030360-5F06-432A-B67A-F470FBB00B3C Q35026607-6357A67E-4C84-4D0B-9504-3C1FB8DE1EC2 Q35190498-F9CB8A80-3785-4D8A-9E60-60F164D12486 Q35224649-1CBC0EC5-445E-4244-82DE-D1D653040E99 Q35603288-9EED3278-C415-44F4-8AE2-F0D828F6F75B

P2860

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

http://www.wikidata.org/entity/Q24556635

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Telavancin, a multifunctional ...... esistant Staphylococcus aureus

@ast

Telavancin, a multifunctional ...... esistant Staphylococcus aureus

@en

Telavancin, a multifunctional ...... esistant Staphylococcus aureus

@nl

type

label

Telavancin, a multifunctional ...... esistant Staphylococcus aureus

@ast

Telavancin, a multifunctional ...... esistant Staphylococcus aureus

@en

Telavancin, a multifunctional ...... esistant Staphylococcus aureus

@nl

prefLabel

Telavancin, a multifunctional ...... esistant Staphylococcus aureus

@ast

Telavancin, a multifunctional ...... esistant Staphylococcus aureus

@en

Telavancin, a multifunctional ...... esistant Staphylococcus aureus

@nl

P1433

Q24556635-843A73D7-084E-4B33-A7E8-CA9D1A2CB04D

P1476

Q24556635-E0615900-C1D9-419E-8B9D-8081501B10E3

P2093

Q24556635-237B5D02-F7CD-4902-8087-2F248ABABDD1

Q24556635-26DFA09D-0562-4CFA-95C4-BEB4ECE23E4E

Q24556635-3805066D-1F5F-40E9-8FF5-E8B8A99A42A8

Q24556635-3AFE42A1-55D1-4B74-A904-EF171A81416A

Q24556635-68328F61-C83F-496F-864B-585CDFA904B8

Q24556635-80660118-720C-44E4-BBAF-FF218E7EB4A7

Q24556635-844F6CD2-627E-423C-B088-857FA368A684

Q24556635-86CE07D0-8691-49A0-8F9C-1CA744BF01BB

Q24556635-8F6BBC76-5E2A-4A7C-A262-6CEDEB1F9017

Q24556635-99C359EA-352F-46B0-8E1A-4017F00AD991

P2860

Q24556635-016F890A-F901-48F7-9BA0-54DAF538E5DC

Q24556635-072B7EDB-7823-4046-B5E1-271DA231EEC0

Q24556635-0BFE1203-DFDD-4396-8A6C-E5EE7778C4F1

Q24556635-0DF79144-B66F-403A-B868-065F97C02424

Q24556635-12ED9885-4601-4D40-863B-EB1BD4955465

Q24556635-13F5AA55-AC14-48C9-BF4A-6EFBE3CA7684

Q24556635-179C4C77-1A67-40C8-BF4C-0AE71B78B722

Q24556635-1D41FA5F-7058-4623-862F-F2B2C280ACDE

Q24556635-1EF9DABB-1100-4B8C-A405-5C4EF6359EC4

Q24556635-22627AE4-2DAB-421C-A013-46D6597269EA

P304

Q24556635-1F9124C2-3845-49D5-B204-694D8CAC54E9

P31

Q24556635-CCC78CF9-461D-43DF-B901-284E4901BA4B

P3181

Q24556635-07DF0627-58A0-48C8-82B8-49CFC4201019

P356

Q24556635-68D0BA72-AEF4-4362-89CD-8C8C1A4AA6E3

P407

Q24556635-77D06527-E3C5-47D6-A2B7-D29F44564F6D

P433

Q24556635-49288DA1-B542-4FC6-9D6B-CFA4AD4B4EA5

P478

Q24556635-D2042448-9858-4E18-BF2C-9F22EAC40EC2

P50

Q24556635-866C4D1F-BF1F-4975-98D5-0B62B94A9EDE

P577

Q24556635-F69DBD0A-95BE-403C-826E-52B55579BAB4

P698

Q24556635-F845CB3B-B9F0-48A0-B1B7-8469DDC5ACDE

P921

Q24556635-767C5849-CD4F-4FB9-B815-BB0E3E07A3D1

Q24556635-D64E98DD-DFA1-4527-9446-6C3C4BEA49E5

P932

Q24556635-43B910B8-D7B2-4FEC-BEE3-80E34CD70F08

P3181

P356

AAC.49.3.1127-1134.2005

P1433

Antimicrobial Agents and Chemotherapy

P1476

Telavancin, a multifunctional ...... esistant Staphylococcus aureus

@en

P2093

Bret M Benton

http://www.w3.org/2001/XMLSchema#string

Dane E Karr

http://www.w3.org/2001/XMLSchema#string

Deborah L Higgins

http://www.w3.org/2001/XMLSchema#string

Dmitri V Debabov

http://www.w3.org/2001/XMLSchema#string

Donald E Schmidt

http://www.w3.org/2001/XMLSchema#string

Erik Sandvik

http://www.w3.org/2001/XMLSchema#string

Joey Leung

http://www.w3.org/2001/XMLSchema#string

Kevin M Krause

http://www.w3.org/2001/XMLSchema#string

Koné Kaniga

http://www.w3.org/2001/XMLSchema#string

Patrick P Humphrey

http://www.w3.org/2001/XMLSchema#string

P2860

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION

Fluorescent method for monitoring cheese starter permeabilization and lysis.

Identification and characterization of a new gene of Escherichia coli K-12 involved in outer membrane permeability.

In vitro antibacterial activities of platelet microbicidal protein and neutrophil defensin against Staphylococcus aureus are influenced by antibiotics differing in mechanism of action.

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

Staphylococcus aureus resistant to vancomycin--United States, 2002.

Glycopeptide derivatives.

Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli.

Structure, biochemistry and mechanism of action of glycopeptide antibiotics.

Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate.

P304

1127-1134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3087651

http://www.w3.org/2001/XMLSchema#string

P356

10.1128/AAC.49.3.1127-1134.2005

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey Michael Hubbard

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15728913

http://www.w3.org/2001/XMLSchema#string

P921

methicillin-resistant Staphylococcus aureus

P932

549257

http://www.w3.org/2001/XMLSchema#string